首页> 外文OA文献 >Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms.
【2h】

Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms.

机译:霍奇金淋巴瘤新兴放射治疗技术:晚期放射诱发的毒性与继发性恶性肿瘤之间的权衡。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Purpose of this study is to explore the trade-offs between radio-induced toxicities and second malignant neoplasm (SMN) induction risk of different emerging radiotherapy techniques for Hodgkin's lymphoma (HL) through a comprehensive dosimetric analysis on a representative clinical model.Methods: Three different planning target volume (PTVi) scenarios of a female patient with supradiaphragmatic HL were used as models for the purpose of this study. Five treatment radiation techniques were simulated: an anterior-posterior parallel-opposed (AP-PA), a forward intensity modulated (FIMRT), an inverse intensity modulated (IMRT), a Tomotherapy (TOMO), a proton (PRO) technique. A radiation dose of 30 Gy or CGE was prescribed. Dose-volume histograms of PTVs and organs-at-risk (OARs) were calculated and related to available dose-volume constraints. SMN risk for breasts, thyroid, and lungs was estimated through the Organ Equivalent Dose model considering cell repopulation and inhomogeneous organ doses. Results: With similar level of PTVi coverage, IMRT, TOMO and PRO plans generally reduced the OARs' dose and accordingly the related radio-induced toxicities. However, only TOMO and PRO plans were compliant with all constraints in all scenarios. For the IMRT and TOMO plans an increased risk of development of breast, and lung SMN compared with AP-PA and FIMRT techniques was estimated. Only PRO plans seemed to reduce the risk of predicted SMN compared with AP-PA technique.Conclusions: Our model-based study supports the use of advanced RT techniques to successfully spare OARs and to reduce the risk of radio-induced toxicities in HL patients. However, the estimated increase of SMNs' risk inherent to TOMO and IMRT techniques should be carefully considered in the evaluation of a risk-adapted therapeutic strategy. © 2013 Cella et al.; licensee BioMed Central Ltd.
机译:背景:本研究的目的是通过对代表性临床模型进行全面的剂量学分析,探讨不同新兴放射疗法对霍奇金淋巴瘤(HL)的放射诱导毒性与第二恶性肿瘤(SMN)诱导风险之间的取舍。 :对于本研究目的,使用女性的a上HL的三种不同的计划目标体积(PTVi)情景作为模型。模拟了五种放射治疗技术:前后平行对置(AP-PA),正向强度调制(FIMRT),反强度调制(IMRT),断层扫描(TOMO),质子(PRO)技术。规定了30 Gy或CGE的辐射剂量。计算了PTV和高危器官(OAR)的剂量-体积直方图,并与可用的剂量-体积约束相关。考虑到细胞重新聚集和器官剂量不均匀,通过器官当量剂量模型评估了SMN对乳房,甲状腺和肺的风险。结果:在PTVi覆盖水平相似的情况下,IMRT,TOMO和PRO计划通常减少了OAR的剂量,并因此降低了相关的放射性诱发的毒性。但是,在所有情况下,只有TOMO和PRO计划符合所有约束。对于IMRT和TOMO计划,估计与AP-PA和FIMRT技术相比,乳腺和肺SMN发生风险增加。结论:我们的基于模型的研究支持使用先进的RT技术成功地节省OAR,并降低HL患者放射致毒性的风险。只有PRO计划似乎可以降低预测的SMN风险。但是,在评估适合风险的治疗策略时,应谨慎考虑TOMO和IMRT技术固有的SMN风险估计增加。 ©2013 Cella等;被许可人BioMed Central Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号